MGVS was established by Professors Moshe Flugelman and Basil Lewis in August 2000 in Lady Davis Carmel Medical Center. The company develops unique
cell-based therapies for large patient populations who suffer from
cardiovascular and other vascular-related conditions and cannot
be treated adequately with existing therapeutic modalities.
The company's two leading products, MultiGeneAngio and MultiGeneGraft, had been approved by the FDA for clinical studies. Two phase I/II clinical trials with MultiGeneAngio had been completed between February 2007 and August 2011. Twelve patients with intermittent claudication were initially treated in two leading medical centers in the USA (the University of Michigan and the University of Pennsylvania). In a second trial, 23 patients with critical limb ischemia were treated in seven medical centers in Israel. Results demonstrated product safety and promising clinical efficacy.